健择在晚期非小细胞肺癌一线化疗中的地位迄今为止,已经有十多种药物被批准用于NSCLC的姑息性治疗;与其他晚期肿瘤如乳腺癌相比,晚期NSCLC患者由于生存期较短,很少有机会能够接受多线治疗,因此选择合适的一线化疗方案显得尤为重要。健择(Gemcitabine)是一种抗瘤谱很广的抗代谢 Gemcitabine in first-line chemotherapy for advanced non-small cell lung cancer To date, more than a dozen drugs have been approved for palliative treatment of NSCLC; patients with advanced NSCLC have shorter survival than other advanced cancers, such as breast cancer , Rarely have the opportunity to accept multi-line treatment, so choose the right first-line chemotherapy program is particularly important. Gemcitabine is a very anti-tumor spectrum